Cycloserine- and Fluoroquinolone-Induced Seizure in Multidrug-Resistance Tuberculosis (MDR-TB) Patient: A Case Report
Downloads
Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a type of tuberculosis (TB) that is resistant to at least two of the most effective first-line anti-TB drugs, isoniazid (H) and rifampicin (R). Cycloserine (Cs) and levofloxacin (Lfx) are second-line anti-TB drugs used in MDR-TB therapy. Even though they are considered to have high effectiveness, both drugs have the potential to cause side effects. One important side effect is neurotoxicity. Seizures have been reported as a common complication of some drugs.
Case: A 39-year-old man was diagnosed with MDR-TB and was treated with individual regimens consisting of Lfx, bedaquiline (Bdq), linezolid (Lzd), clofazimine (Cfz), and Cs. After consuming anti-TB drugs for 27 days, the patient had seizures several times. The patient experienced full-body seizures and loss of consciousness during the seizures. Cs and Lfx were discontinued and replaced by other regimens. Serial electroencephalogram (EEG) showed normal results. After Cs and Lfx were discontinued, the patient never had another seizure.
Conclusion: Management of MDR-TB is sometimes complicated because of severe drug side effects. Patients taking Cs and fluoroquinolones (FQs) should be advised to report any sign of seizure or changes in mental status to their healthcare provider.
(WHO) WHO. Multidrug-Resistant Tuberculosis (MDR-TB). Geneva, https://www.who.int/publications/m/item/multidrug-resistant-tuberculosis-(mdr-tb) (2018).
(WHO) WHO. Global Tuberculosis Report 2021. Geneva, https://www.who.int/publications-detail-redirect/9789240037021 (2021).
(WHO) WHO. Global Tuberculosis Report 2022. Geneva, https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (2022).
(WHO) WHO. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Susceptible Tuberculosis Treatment. Geneva, https://www.who.int/publications/i/item/9789240048126 (2022).
Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia, 2020.
Huruba M, Farcas A, Leucuta DC, et al. A VigiBase Descriptive Study of Fluoroquinolone-Associated Peripheral Nervous System Disorders. Pharmaceuticals (Basel); 15. Epub ahead of print January 2022. [PubMed]
Rezaei NJ, Bazzazi AM, Alavi SAN. Neurotoxicity of the Antibiotics: A Comprehensive Study. Neurol India 2018; 66: 1732–1740. [PubMed]
Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric Toxicity and Cycloserine Concentrations during Treatment for Multidrug-Resistant Tuberculosis. Int J Infect Dis 2021; 105: 688–694. [PubMed]
Indriani L, Renitia GI, Setiani LA. Treatment Duration and Drug Regimen Correlation with Side Effects Incidence in Drug-Resistant Tuberculosis (DR-TB) Patients at Pulmonary Hospital. JSFK (Jurnal Sains Farm Klin 2023; 10: 320–326. [Journal]
(WHO) WHO. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Resistant Tuberculosis Treatment. Geneva, https://www.who.int/publications/i/item/9789240007048 (2020).
Espinosa-Pereiro J, Sánchez-Montalvá A, Aznar ML, et al. MDR Tuberculosis Treatment. Medicina (Kaunas); 58. Epub ahead of print January 2022. [PubMed]
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. Jakarta, https://tbindonesia.or.id/wp-content/uploads/2021/06/TBRO_Buku-Juknis-Tuberkulosis-2020-Website.pdf (2020).
Prasad R, Singh A, Gupta N. Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis. Ann Natl Acad Med Sci 2021; 57: 15–35. [Journal]
Chen H-Y, Albertson TE, Olson KR. Treatment of Drug-Induced Seizures. Br J Clin Pharmacol 2016; 81: 412–419. [PubMed]
Huff JS, Murr N. Seizure. Treasure Island (FL), 2023. [PubMed]
Ausi Y, Santoso P, Sunjaya DK, et al. Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy. Patient Prefer Adherence 2021; 15: 2597–2607. [PubMed]
Singhal P, Lunia P, Salgia K, et al. Incidence of Cycloserine Induced Neurotoxicity in Drug Resistant TB Patients Attending a Tertiary Care Hospital. Eur Respir J 2020; 56: 1593. [Journal]
Vilchèze C. Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. Applied Sciences; 10. Epub ahead of print 2020. [Journal]
Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment Correlates of Successful Outcomes in Pulmonary Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Lancet 2018; 392: 821–834. [PubMed]
Wang J, Pang Y, Jing W, et al. Efficacy and Safety of Cycloserine-Containing Regimens in the Treatment of Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study in China. Infect Drug Resist 2019; 12: 763–770. [PubMed]
Belete TM. Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis. Microbiol Insights 2022; 15: 11786361221099878. [PubMed]
Yadav S, Rawal G. Adverse Drug Reactions Due to Cycloserine on the Central Nervous System in the Multidrug-Resistant Tuberculosis Cases: A Case Series. PAMJ Clin Med 2019; 1: 25. [Journal]
Borisov S, Danila E, Maryandyshev A, et al. Surveillance of Adverse Events in the Treatment of Drug-Resistant Tuberculosis: First Global Report. Eur Respir J; 54. Epub ahead of print December 2019. [PubMed]
Hotha P, Grover S, Gupta R. Cycloserine Induced Psychosis, Insomnia and Suicidal Attempts in a Young Female Patient with Pre-Extensively Drug Resistant Tuberculosis. J Pharm Care; 10. Epub ahead of print 31 December 2022. [Journal]
Al-Shaer MH, Alghamdi WA, Alsultan A, et al. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment to Guide Dose Selection. Antimicrob Agents Chemother; 63. Epub ahead of print July 2019. [PubMed]
Bahuguna A, Rawat DS. An Overview of New Antitubercular Drugs, Drug Candidates, and Their Targets. Med Res Rev 2020; 40: 263–292. [PubMed]
Khan T, Sankhe K, Suvarna V, et al. DNA Gyrase Inhibitors: Progress and Synthesis of Potent Compounds as Antibacterial Agents. Biomed Pharmacother 2018; 103: 923–938. [PubMed]
Rusu A, Munteanu A-C, Arbănași E-M, et al. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile? Pharmaceutics; 15. Epub ahead of print March 2023. [PubMed]
Kang YA, Shim TS, Koh W-J, et al. Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Ann Am Thorac Soc 2016; 13: 364–370. [PubMed]
Nishikubo M, Kanamori M, Nishioka H. Levofloxacin-Associated Neurotoxicity in a Patient with a High Concentration of Levofloxacin in the Blood and Cerebrospinal Fluid. Antibiotics (Basel, Switzerland); 8. Epub ahead of print June 2019. [PubMed]
Ngoc NB, Vu Dinh H, Thuy NT, et al. Active Surveillance for Adverse Events in Patients on Longer Treatment Regimens for Multidrug-Resistant Tuberculosis in Viet Nam. PLoS One 2021; 16: e0255357. [PubMed]
Lan Z, Ahmad N, Baghaei P, et al. Drug-Associated Adverse Events in the Treatment of Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Lancet Respir Med 2020; 8: 383–394. [PubMed]
Abdulaziz ATA, Li J, Zhou D. The Prevalence, Characteristics and Outcome of Seizure in Tuberculous Meningitis. Acta Epileptol 2020; 2: 1. [Journal]
Setiawan I, Harsono Harsono, Asmedi A. EEG Awal Terapi sebagai Prediktor Kekambuhan pada Penderita Epilepsi yang Mendapat Terapi Obat Antiepilepsi. Biomedika 2018; 15–19. [Journal]
Copyright (c) 2024 Dewi Behtri Yanifitri, Yunita Arliny, Wilia Aprilisa Utami, Wira Winardi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (